A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Trial Profile

A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Gemcitabine (Primary) ; MSB 0011359C (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 May 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 23 May 2018.
    • 26 Apr 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Apr 2018 to 1 May 2018.
    • 12 Apr 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 16 Apr 2018 to 26 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top